candesartan cilexetil has been researched along with Arrhythmia in 5 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
| Excerpt | Relevance | Reference |
|---|---|---|
| "trans-1,2-Cyclohexanediol, the major metabolite of the cilexetil moiety of candesartan cilexetil (CC), has been reported to have potent pro-arrhythmic effects in dogs with congestive heart failure (CHF), especially when co-administered with digoxin." | 7.72 | Absence of interactive effects of trans-1,2-cyclohexanediol, a major metabolite of the side-chain of candesartan cilexetil, on digoxin-induced arrhythmias in dogs. ( Chatani, F; Kitayoshi, T; Nishimura, S; Watanabe, T; Yamamoto, K, 2003) |
| "To evaluate the preventive effect of regression of left ventricular hypertrophy (LVH) on sudden cardiac death (SCD), the incidence of ventricular tachycardia or ventricular fibrillation (VT/Vf) after left coronary artery occlusion in Langendorff preparations was studied in the following five groups: (1) spontaneously hypertensive rats (SHR) without treatment (SHR-N), (2) SHR treated with captopril (SHR-C), (3) SHR treated with the angiotensin II receptor antagonist TCV-116 (SHR-A), (4) SHR treated with hydralazine (SHR-H), and (5) Wistar-Kyoto (WKY) rats." | 7.69 | Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade. ( Kanno, M; Kitabatake, A; Kohya, T; Nakaya, H; Saito, H; Tohse, N; Yokoshiki, H, 1995) |
| "trans-1,2-Cyclohexanediol, the major metabolite of the cilexetil moiety of candesartan cilexetil (CC), has been reported to have potent pro-arrhythmic effects in dogs with congestive heart failure (CHF), especially when co-administered with digoxin." | 3.72 | Absence of interactive effects of trans-1,2-cyclohexanediol, a major metabolite of the side-chain of candesartan cilexetil, on digoxin-induced arrhythmias in dogs. ( Chatani, F; Kitayoshi, T; Nishimura, S; Watanabe, T; Yamamoto, K, 2003) |
| " cefotiam hexetil) and an antihypertensive agent (candesartan cilexetil), were examined in beagles that were made congestive heart failure (CHF) by rapid ventricular pacing." | 3.71 | Cardiotoxic interaction of metabolites from a prodrug segment cilexetil (cyclohexyloxy-carbonyloxy-ethyl) with digoxin in the canine failing heart. ( Kakizoe, E; Okunishi, H; Shimoura, K; Wang, DQ, 2002) |
| "To evaluate the preventive effect of regression of left ventricular hypertrophy (LVH) on sudden cardiac death (SCD), the incidence of ventricular tachycardia or ventricular fibrillation (VT/Vf) after left coronary artery occlusion in Langendorff preparations was studied in the following five groups: (1) spontaneously hypertensive rats (SHR) without treatment (SHR-N), (2) SHR treated with captopril (SHR-C), (3) SHR treated with the angiotensin II receptor antagonist TCV-116 (SHR-A), (4) SHR treated with hydralazine (SHR-H), and (5) Wistar-Kyoto (WKY) rats." | 3.69 | Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade. ( Kanno, M; Kitabatake, A; Kohya, T; Nakaya, H; Saito, H; Tohse, N; Yokoshiki, H, 1995) |
| "Candesartan cilexetil-treated banded rat hearts displayed shorter QT intervals and lower vulnerability to atrial and ventricular tachyarrhythmias than vehicle-treated banded hearts." | 1.72 | Candesartan Cilexetil Attenuates Arrhythmogenicity Following Pressure Overload in Rats via the Modulation of Cardiac Electrical and Structural Remodeling and Calcium Handling Dysfunction. ( Chang, GJ; Chen, WJ; Ko, YS; Lai, YJ; Lee, YS; Yeh, YH, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, GJ | 1 |
| Yeh, YH | 1 |
| Chen, WJ | 1 |
| Ko, YS | 1 |
| Lai, YJ | 1 |
| Lee, YS | 1 |
| Okunishi, H | 1 |
| Shimoura, K | 1 |
| Wang, DQ | 1 |
| Kakizoe, E | 1 |
| Yamamoto, K | 1 |
| Kitayoshi, T | 1 |
| Nishimura, S | 1 |
| Chatani, F | 1 |
| Watanabe, T | 1 |
| Kohya, T | 1 |
| Yokoshiki, H | 1 |
| Tohse, N | 1 |
| Kanno, M | 1 |
| Nakaya, H | 1 |
| Saito, H | 1 |
| Kitabatake, A | 1 |
| Jalowy, A | 1 |
| Schulz, R | 1 |
| Heusch, G | 1 |
1 review available for candesartan cilexetil and Arrhythmia
| Article | Year |
|---|---|
AT1 receptor blockade in experimental myocardial ischemia/reperfusion.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Arrhythmias, Ca | 1999 |
4 other studies available for candesartan cilexetil and Arrhythmia
| Article | Year |
|---|---|
Candesartan Cilexetil Attenuates Arrhythmogenicity Following Pressure Overload in Rats via the Modulation of Cardiac Electrical and Structural Remodeling and Calcium Handling Dysfunction.
Topics: Animals; Arrhythmias, Cardiac; Atrial Remodeling; Benzimidazoles; Biphenyl Compounds; Calcium; Hyper | 2022 |
Cardiotoxic interaction of metabolites from a prodrug segment cilexetil (cyclohexyloxy-carbonyloxy-ethyl) with digoxin in the canine failing heart.
Topics: Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Benzimidazoles; Biphenyl Compounds; Cardiac | 2002 |
Absence of interactive effects of trans-1,2-cyclohexanediol, a major metabolite of the side-chain of candesartan cilexetil, on digoxin-induced arrhythmias in dogs.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Benzimidazoles; Biphenyl Compounds; Cyclohexanols; | 2003 |
Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade.
Topics: Angiotensin II; Animals; Arrhythmias, Cardiac; Benzimidazoles; Biphenyl Compounds; Body Weight; Capt | 1995 |